Replimune is pioneering a new generation of cancer treatments called oncolytic immuno-gene therapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

Oncolytic immuno-gene therapy is expected to enhance the effectiveness of immune checkpoint blockade and become the second cornerstone of immune-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease.